CVRX · CVRx, Inc.
$1.55
+0.02 (+1.31%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$50.49M
Shares
26.64M
Volume · Oct 1
1.46M
Avg daily vol (3M)
884.44K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.53
Open$1.75
Day$1.50–1.79
52W close$1.53–10.81
Avg vol 30d793K
Short int1.6M · 6.2% float · 2.6d
Short vol41%
Last earningsAug 6, 2026
DataJun 2021–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-78.3%
Trailing year
Short interest
6.2%
Latest settlement · 2.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−74%
below
Price vs 50-day avg
−54%
below
RSI (14)
21
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−50%
trailing
6-month return
−79%
trailing
YTD return
−78%
this year
Relative strength
−91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +8 funds added
Insider flow
Accumulating
Net +$76.4K over 90 days · 0% sells
Short interest
Falling
6.17% of float · ▼ -16.5% MoM · 2.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
88 holders — mid 3-yr range
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
85%
expanding
EPS growth
+23%
Y/Y
Free cash flow
$-40.8M
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
18.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full year of 2026
Total revenue
Initiated
$58M – $60M
prior FY $56.65M
midpoint +4.1% Y/Y
Gross margin
Initiated
86% – 87%
Operating expenses
Initiated
$99M – $101M
third quarter of 2026
Total revenue
Initiated
$13.5M – $14.5M
prior qtr $15.71M
midpoint −10.9% QoQ
Guided vs delivered
· last 8 settled
Total revenue
full year of 2024
guided $50M – $53M
$51.29M
In line
Total revenue
third quarter of 2024
guided $12.7M – $13.7M
$13.37M
In line
Total revenue
second quarter of 2024
guided $11.3M – $12.3M
$11.81M
In line
Total revenue
first quarter of 2024
guided $11M – $12M
$10.77M
Miss −6.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−74%
Bearish
Price vs 50-day avg
−54%
Bearish
RSI (14)
21
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +8 funds added
Insider flow
Accumulating
Net +$76.4K over 90 days · 0% sells
Short interest
Falling
6.17% of float · ▼ -16.5% MoM · 2.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
88 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $11
vs 200-day avg -74%
vs 50-day avg -54%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active implanting centers in the U.S. | 258 | Q2 2026 | — |
| Revenue units in the U.S. | 466 | Q2 2026 | — |
| Total revenue units in Europe | 40 | Q2 2026 | — |
| U.S. sales territories | 56 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVRX
this stock
CVRx, Inc.
|
$50.49M | -78.5% | +10.4% | — | 6.2% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.8% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.0% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -22.3% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.7% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVRX | -39.5% | -50.2% | -78.6% | -12.6% | -78.5% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -39.1% | -50.0% | -91.1% | -12.8% | -90.5% |